222 related articles for article (PubMed ID: 20508996)
1. Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies.
Lohse S; Peipp M; Beyer T; Valerius T; Dechant M
Arch Immunol Ther Exp (Warsz); 2010 Aug; 58(4):303-12. PubMed ID: 20508996
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation.
Russell MW; Reinholdt J; Kilian M
Eur J Immunol; 1989 Dec; 19(12):2243-9. PubMed ID: 2606139
[TBL] [Abstract][Full Text] [Related]
4. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
[TBL] [Abstract][Full Text] [Related]
6. Activation of effector functions by immune complexes of mouse IgG2a with isotype-specific autoantibodies.
Rajnavölgyi E; Fazekas G; Lund J; Daeron M; Teillaud JL; Jefferis R; Fridman WH; Gergely J
Immunology; 1995 Apr; 84(4):645-52. PubMed ID: 7540592
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens.
Dhein J; Daniel PT; Trauth BC; Oehm A; Möller P; Krammer PH
J Immunol; 1992 Nov; 149(10):3166-73. PubMed ID: 1431095
[TBL] [Abstract][Full Text] [Related]
10. Structural difference in the complement activation site of human IgG1 and IgG3.
Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
[TBL] [Abstract][Full Text] [Related]
11. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
12. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.
Strome SE; Sausville EA; Mann D
Oncologist; 2007 Sep; 12(9):1084-95. PubMed ID: 17914078
[TBL] [Abstract][Full Text] [Related]
13. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).
Klausz K; Berger S; Lammerts van Bueren JJ; Derer S; Lohse S; Dechant M; van de Winkel JG; Peipp M; Parren PW; Valerius T
Cancer Sci; 2011 Oct; 102(10):1761-8. PubMed ID: 21718386
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
Masui H; Kawamoto T; Sato JD; Wolf B; Sato G; Mendelsohn J
Cancer Res; 1984 Mar; 44(3):1002-7. PubMed ID: 6318979
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell lysis and tumor growth inhibition by the isotype variants of MAb BR55-2 directed against Y oligosaccharide.
Steplewski Z; Lubeck MD; Scholz D; Loibner H; McDonald Smith J; Koprowski H
In Vivo; 1991; 5(2):79-83. PubMed ID: 1768791
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of synergistic complement-mediated lysis of rat red cells by monoclonal IgG antibodies.
Hughes-Jones NC; Gorick BD; Howard JC
Eur J Immunol; 1983 Aug; 13(8):635-41. PubMed ID: 6603980
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
18. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions.
Lucisano Valim YM; Lachmann PJ
Clin Exp Immunol; 1991 Apr; 84(1):1-8. PubMed ID: 1707767
[TBL] [Abstract][Full Text] [Related]
19. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies.
Kawase I; Komuta K; Ogura T; Fujiwara H; Hamaoka T; Kishimoto S
Cancer Res; 1985 Apr; 45(4):1663-8. PubMed ID: 3978634
[TBL] [Abstract][Full Text] [Related]
20. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
Kinouchi T; Bander NH; Kotake T
J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
